Home›Screener›AURA›Profile
C
53/100

Aura Biosciences

AURAOcular Oncology
← Signals View
📋
Analyst Summary
✓ VERIFIED2026-04-11

Aura Biosciences (AURA) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 1 Phase 2[2], 1 Phase 1[3].

Trial NCT06007690[5] evaluates Bel-sar in Choroidal Melanoma with a target enrollment of 100 participants.

Sources

  1. ClinicalTrials.gov (2026-04-11) ↗
  2. ClinicalTrials.gov (2026-04-11) ↗
  3. ClinicalTrials.gov (2026-04-11) ↗
  4. ClinicalTrials.gov (2026-04-11) ↗
  5. ClinicalTrials.gov · NCT06007690 (2026-03-02) ↗
🔬
Clinical Trials
5
NCT03941379Choroidal Melanoma, Indeterminate Lesions of Eye
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05483868Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06007690Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06643884Eye Cancer, Primary Cancer
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07421739Choroidal Melanoma, Indeterminate Lesions, Uveal Melanoma, Ocular Melanoma
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
0 filings
Source ↗
sec_edgar · Retrieved 2026-04-10
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials4
Data Provenance
cik1 verified
clinical trial5 verified
insider buy1 verified
trial count4 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR